nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

26.11.2016 | General Gynecology

Elevated RON protein expression in endometriosis and disease-associated ovarian cancers

verfasst von: Ping Xu, Shaojie Ding, Libo Zhu, Fang Le, Xiufeng Huang, Yonghong Tian, Xinmei Zhang

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Recepteur d’origine nantais (RON) protein expression has been demonstrated to correlate with tumor progression, metastasis, and prognosis, and its mRNA expression increases in deeply infiltrating endometriotic lesions. However, it remains unclear whether RON protein expression also increases in endometriotic lesions, and may be a risk factor of malignant transformation in endometriotic lesions.

Methods

The protein expression of RON in control (n = 19), eutopic (n = 16), and ectopic (n = 51) endometria, as well as in endometriosis-associated ovarian cancers (EAOC, n = 16) was determined by immunohistochemical (IHC) staining.

Results

Endometriotic lesions expressed low levels of RON protein, but no RON protein expression appeared in matched eutopic or control endometrium. EAOC exhibited high levels of RON protein. The frequency and IHC score of RON protein expression were both significantly higher in EAOC [100.0% (14/14), 5.37 ± 0.74] than those in endometriotic lesions [51.0% (26/51), 2.15 ± 1.12; P = 0.002, 0.001]. Multivariate analysis of covariance only revealed a correlation of RON protein expression and EAOC (P = 0.006), but no correlations of RON protein expression and clinical parameters (P > 0.05).

Conclusions

These obtained results suggest that increased RON expression might be involved in the pathogenesis of endometriosis and disease-associated ovarian cancers.

Sun Y, Che X, Zhu L, Zhao M, Fu G, Huang X et al (2012) Pigment epithelium derived factor inhibits the growth of human endometrial implants in nude mice and of ovarian endometriotic stromal cells in vitro. PLoS One 7(9):e45223CrossRefPubMedPubMedCentral

Becker CM, D’Amato RJ (2007) Angiogenesis and antiangiogenic therapy in endometriosis. Microvasc Res 74(2):121–130CrossRefPubMed

May K, Becker C (2008) Endometriosis and angiogenesis. Minerva Ginecol 60(3):245–254PubMed

Fukunaga M, Nomura K, Ishikawa E, Ushigome S (1997) Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology 30(3):249–255CrossRefPubMed

Bayramođlu H, Düzcan E (2001) Atypical epithelial changes and mutant p53 gene expression in ovarian endometriosis. Pathol Oncol Res 7(1):33–38CrossRef

Moll UM, Chumas JC, Chalas E, Mann WJ (1990) Ovarian carcinoma arising in atypical endometriosis. Obstet Gynecol 75(3, Part 2):537–539

Mandai M, Yamaguchi K, Matsumura N, Baba T, Konishi I (2009) Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int J Clin Oncol 14(5):383–391CrossRefPubMed

Ouellet V, Guyot MC, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN et al (2006) Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 119(3):599–607CrossRefPubMed

Park JH, Park EJ, Lee HS, Kim SJ, Hur SK, Imbalzano AN et al (2006) Mammalian SWI/SNF complexes facilitate DNA double-strand break repair by promoting γ-H2AX induction. EMBO J 25(17):3986–3997CrossRefPubMedPubMedCentral

10.

Park J-H, Park E-J, Hur S-K, Kim S, Kwon J (2009) Mammalian SWI/SNF chromatin remodeling complexes are required to prevent apoptosis after DNA damage. DNA Repair 8(1):29–39CrossRefPubMed

11.

Lee HS, Park JH, Kim SJ, Kwon SJ, Kwon J (2010) A cooperative activation loop among SWI/SNF, γ-H2AX and H3 acetylation for DNA double-strand break repair. EMBO J 29(8):1434–1445CrossRefPubMedPubMedCentral

12.

Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O (2012) Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol 25(4):615–624CrossRefPubMed

13.

Chene G, Tchirkov A, Pierre-Eymard E, Dauplat J, Raoelfils I, Cayre A et al (2013) Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions. Clin Cancer Res 19(11):2873–2882CrossRefPubMed

14.

Chene G, Ouellet V, Rahimi K, Barres V, Caceres K, Meunier L et al (2015) DNA damage signaling and apoptosis in preinvasive tubal lesions of ovarian carcinoma. Int J Gynecol Cancer 25(5):761–769CrossRefPubMed

15.

Ronsin C, Muscatelli F, Mattei M, Breathnach R (1993) A novel putative receptor protein tyrosine kinase of the met family. Oncogene 8(5):1195–1202PubMed

16.

Wang M-H, Wang D, Chen Y-Q (2003) Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis 24(8):1291–1300CrossRefPubMed

17.

Camp ER, Liu W, Fan F, Yang A, Somcio R, Ellis LM (2005) RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol 12(4):273–281CrossRefPubMed

18.

Kang CM, Babicky ML, Lowy AM (2014) The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies. Pancreas 43(2):183CrossRefPubMedPubMedCentral

19.

Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zucconi A, Santaguida S et al (2008) Prognostic role of the recepteur d’origine nantais (RON) expression in ovarian cancer patients. Gynecol Oncol 111(2):237–243CrossRefPubMed

20.

Bieniasz M, Radhakrishnan P, Faham N, De La OJ-P, Welm AL (2015) Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3 K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts. Clin Cancer Res 21(24):5588–5600CrossRefPubMedPubMedCentral

21.

Zhang X, Qi C, Lin J (2010) Enhanced expressions of matrix metalloproteinase (MMP)-2 and–9 and vascular endothelial growth factors (VEGF) and increased microvascular density in the endometrial hyperplasia of women with anovulatory dysfunctional uterine bleeding. Fertil Steril 93(7):2362–2367CrossRefPubMed

22.

Matsuzaki S, Canis M, Pouly J, Dechelotte P, Okamura K, Mage G (2005) The macrophage stimulating protein/RON system: a potential novel target for prevention and treatment of endometriosis. Mol Hum Reprod 11(5):345–349CrossRefPubMed

23.

Matsuzaki S, Canis M, Vaurs-Barrière C, Boespflug-Tanguy O, Dastugue B, Mage G (2005) DNA microarray analysis of gene expression in eutopic endometrium from patients with deep endometriosis using laser capture microdissection. Fertil Steril 84:1180–1190CrossRefPubMed

24.

Huang X, Chen L, Fu G, Xu H, Zhang X (2012) Decreased expression of pigment epithelium-derived factor and increased microvascular density in ovarian endometriotic lesions in women with endometriosis. Euro J Obstet Gynecol Reprod Biol 165(1):104–109CrossRef

25.

Romero I, Bast RC Jr (2012) Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology 153(4):1593–1602CrossRefPubMedPubMedCentral

26.

Neto JS, Kho RM, dos Santos Siufi DF, Baracat EC, Anderson KS, Abrão MS (2014) Cellular, histologic, and molecular changes associated with endometriosis and ovarian cancer. J Mini Invasive Gynecol 21(1):55–63CrossRef

27.

Maggiora P, Lorenzato A, Fracchioli S, Costa B, Castagnaro M, Arisio R et al (2003) The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res 288(2):382–389CrossRefPubMed

28.

Otsuka J, Okuda T, Sekizawa A, Amemiya S, Saito H, Okai T et al (2004) K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma. Med Electron Microsc 37(3):188–192CrossRefPubMed

29.

Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11(1):63–70CrossRefPubMed

30.

Yamamoto S, Tsuda H, Takano M, Iwaya K, Tamai S, Matsubara O (2011) PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol 225(2):189–194CrossRefPubMed

31.

Lin K, Zhan H, Ma J, Xu K, Wu R, Zhou C et al (2014) Increased steroid receptor RNA activator protein (SRAP) accompanied by decreased estrogen receptor-beta (ER-β) levels during the malignant transformation of endometriosis associated ovarian clear cell carcinoma. Acta Histochem 116(5):878–882CrossRefPubMed

32.

De Bortoli M, Di Renzo MF, Costantino A, Sismondi P, Comoglio PM (1998) Overexpression of the RON gene in human breast carcinoma. Oncogene 16:2927–2933CrossRefPubMed

33.

Chen Y-Q, Zhou Y-Q, Angeloni D, Kurtz AL, Qiang X-Z, Wang M-H (2000) Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. Exp Cell Res 261(1):229–238CrossRefPubMed

34.

Wang M-H, Kurtz AL, Chen Y-Q (2000) Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis 21(8):1507–1512CrossRefPubMed

35.

Cheng H, Liu H, Lin Y, Chen HH, Hsu P, Chang T et al (2005) Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer 92(10):1906–1914CrossRefPubMedPubMedCentral

36.

Xu X-M, Wang D, Shen Q, Chen Y-Q, Wang M-H (2004) RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Oncogene 23(52):8464–8474CrossRefPubMed

37.

Chang K, Karnad A, Zhao S, Freeman JW (2015) Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets. Oncotarget 6(6):3507–3518CrossRefPubMedPubMedCentral

38.

Kim H, Kim T, Chung H, Song Y (2014) Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. Br J Cancer 110(7):1878–1890CrossRefPubMedPubMedCentral

39.

Xiangming X, Yun Q, Guoliang Z, Jianjiang L, Lisong T (2011) Mechanisms of RON-mediated epithelial-mesenchymal transition in MDCK cells through the MAPK pathway. Brazilian J Medical and Biol Res = Revista brasileira de pesquisas médicas e biológicas/Sociedade Brasileira de Biofísica [et al] 44(7):634–641

40.

Qi M, Guin S, Padhye SS, Zhou YQ, Zhang RW, Wang MH (2011) Ribosomal Protein S6 Kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein. Mol Cancer 10(1):1–15CrossRef

41.

Minetto M (1998) Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the ron receptor. Oncogene 17(6):741–749CrossRefPubMed

42.

Zhou YQ, He C, Chen YQ, Wang D, Wang MH (2003) Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene 22(2):186–197CrossRefPubMed

Titel: Elevated RON protein expression in endometriosis and disease-associated ovarian cancers
verfasst von: Ping Xu
Shaojie Ding
Libo Zhu
Fang Le
Xiufeng Huang
Yonghong Tian
Xinmei Zhang
Publikationsdatum: 26.11.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 3/2017
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-016-4248-x

Neu im Fachgebiet Gynäkologie und Geburtshilfe

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Elevated RON protein expression in endometriosis and disease-associated ovarian cancers

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hochrisiko-Eingriffe für postoperative Übelkeit

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Gynäkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Current practice patterns for management of vulvodynia in the United States

Increased expression of miR-15b is associated with clinicopathological features and poor prognosis in cervical carcinoma

Usage of the levonorgestrel-releasing intrauterine system (LNG-IUS) in adolescence: what is the evidence so far?

Retrospective cohort study: AMH is the best ovarian reserve markers in predicting ovarian response but has unfavorable value in predicting clinical pregnancy in GnRH antagonist protocol

Therapeutic effect of acupuncture on the outcomes of in vitro fertilization: a systematic review and meta-analysis

Meta-analysis demonstrates no association between p16 ink4a promoter methylation and epithelial ovarian cancer

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hochrisiko-Eingriffe für postoperative Übelkeit

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Gynäkologie